Focused On-demand Library for Cytochrome c oxidase assembly factor 3 homolog, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y2R0

UPID:

COA3_HUMAN

Alternative names:

Coiled-coil domain-containing protein 56; Mitochondrial translation regulation assembly intermediate of cytochrome c oxidase protein of 12 kDa

Alternative UPACC:

Q9Y2R0; A8K498

Background:

Cytochrome c oxidase assembly factor 3 homolog, mitochondrial, also known as Coiled-coil domain-containing protein 56, plays a pivotal role in the mitochondrial respiratory chain. It is a core component of the MITRAC complex, crucial for the regulation of cytochrome c oxidase assembly. This protein ensures the efficient translation of MT-CO1 and the assembly of mitochondrial respiratory chain complex IV, highlighting its essential function in cellular energy production.

Therapeutic significance:

The protein is linked to Mitochondrial complex IV deficiency, nuclear type 14, a disorder marked by developmental delay, cognitive impairment, and motor issues. Understanding the role of Cytochrome c oxidase assembly factor 3 homolog, mitochondrial could open doors to potential therapeutic strategies for this mitochondrial disorder, offering hope for targeted treatments.